Skip to main content
. 2014 May 8;14:80. doi: 10.1186/1471-2466-14-80

Table 5.

Hazard ratios (HRs) of asthma patients by drug used compared to patients without drug use

Variables n (%) HR (95% CI) HR* (95% CI) HR** (95% CI) With steroid HR*** (95% CI) Without steroid HR**** (95% CI)
Steroid
 
 
 
 
 
 
Yes (n = 19720)
1038 (5.3%)
0.68 (0.62-0.73)
0.56 (0.52-0.61)
N/A
N/A
N/A
No (n = 15366)
1158 (7.5%)
 
 
 
 
 
Expectorant
 
 
 
 
 
 
Yes (n = 6818)
339 (5.0%)
0.74 (0.66-0.83)
0.59 (0.53-0.67)
0.63 (0.54-0.74)
0.65 (0.55-0.78)
0.64 (0.57-0.72)
No (n = 28268)
1857 (6.6%)
 
 
 
 
 
Bronchodilators
 
 
 
 
 
 
Yes (n = 19933)
1157 (5.8%)
0.84 (0.77-0.91)
0.67 (0.61-0.72)
0.78 (0.68-0.89)
0.78 (0.69-0.88)
0.78 (0.71-0.85)
No (n = 15153)
1039 (6.9%)
 
 
 
 
 
Anti-muscarinic agents
 
 
 
 
 
 
Yes (n = 4298)
264 (6.1%)
1.00 (0.88-1.14)
0.72 (0.63-0.82)
0.87 (0.75-1.01)
0.86 (0.64-1.14)
0.87 (0.76-0.99)
No (n = 30788)
1932 (6.3%)
 
 
 
 
 
Airway smooth relaxant
 
 
 
 
 
 
Yes (n = 19222)
1245 (6.5%)
1.07 (0.99-1.17)
0.75 (0.69-0.82)
0.88 (0.77-1.02)
0.91 (0.81-1.03)
0.90 (0.82-0.99)
No (n = 15864)
951 (6.0%)
 
 
 
 
 
Leukotriene receptor antagonist
 
 
 
 
 
 
Yes (n = 1432)
46 (3.2%)
0.48 (0.36-0.65)
0.59 (0.44-0.79)
0.72 (0.52-1.00)
0.62 (0.32-1.20)
0.69 (0.52-0.93)
No (n = 33654) 2150 (6.4%)          

Note: HR*, each factor was adjusted for diabetes, hypertension, hyperlipidemia, and heart disease.

CI, confidence interval; n (%), number of participants with CKD and% of participants.

p < 0.05 for comparison between patients with asthma and without asthma; p < 0.001 for comparison between patient with asthma and without asthma.

Hazard ratios (HRs) of asthma patients by drug used. In each drug, the HR was compared with patients without drug. (a) Crude HR (95% CI) for each drug. (b) HR *(95% CI) for each drug, adjusted for co-morbidities. (c) Patients with steroid HR **(95% CI) for each drug, adjusted for co-morbidities. (d) Patients without steroid use HR ***(95% CI) for each drug, adjusted for co-morbidities. (e) HR **** (95% CI) for each drug, adjusted for co-morbidities and steroid use.